Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025
Altimmune, Inc. (NASDAQ: ALT) has become a tightly wound biotech story heading into year‑end 2025. The small‑cap developer of liver and metabolic drugs is changing its CEO just weeks before a pivotal 48‑week readout in its lead MASH trial, while